CULLINAN THERAPEUTICS, INC. (CGEM)

Every figure this model derived for CGEM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2022-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 334,538,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 341,974,000 AssetsCurrent 2026-06-30
current liabilities 40,628,000 LiabilitiesCurrent 2026-06-30
equity 321,754,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-06-30
interest expense 32,000 InterestPaidNet 2022-12-31
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CGEM on one particular measure came for.

RatioValue
current ratio8.42
current ratio reported8.42
dilution pct-10.92
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about CGEM's figures. Written by the derivation as it ran, not added afterwards.